Spinal cord injuries result in permanent loss of motor function, leaving those affected with long term physical and financial burdens. Strategies for spinal cord injury repair must overcome unique challenges due to scar tissue that seals off the injury site, preventing regeneration. Tissue engineering can address these challenges with scaffolds that serve as cell- and drug-delivery tools, replacing damaged tissue while simultaneously addressing the inhibitory environment on a biochemical level. To advance this approach, the choice of cells, biomaterial matrix, and drug delivery system must be investigated and evaluated. This research seeks to evaluate (1) the behaviour of murine induced pluripotent stem cells in previously characterized 3D fibrin matrices; (2) the 3D fibrin matrix as a platform to support the differentiation of human induced pluripotent stem cells; and (3) the ability of an affinity-based drug delivery system to control the release of emerging spinal cord injury therapeutic, heat shock protein 70 from fibrin scaffolds. / Graduate / 0541 / amy.lynn.montgomery@gmail.com

Les porphyries érythropoïétiques (PE) : Porphyrie Erythropoïétique Congénitale -PEC- et Protoporphyrie Erythropoïétique -PPE- sont caractérisées par le déficit d’une des enzymes de la voie de biosynthèse de l’hème. Le traitement curatif des formes sévères de PE est la transplantation de moelle osseuse allogénique (TMOA). La PPE est parfois compliquée d’une insuffisance hépatique majeure nécessitant une greffe hépatique. Dans un modèle murin de PPE (Fechm1Pas/Fechm1Pas), nous avons démontré l’apparition progressive de lésions hépatiques dès la 2ème semaine de vie. Une TMO précoce (nouveau-né) a permis de prévenir l’apparition de ces lésions hépatiques et de corriger la photosensibilité cutanée démontrant l’efficacité de cette approche thérapeutique pour les formes sévères de PPE. La thérapie génique par greffe de cellules souches hématopoïétiques autologues corrigées représente une alternative à la TMOA en l’absence de donneur HLA-compatible. Nous avons développé des cellules souches pluripotentes induites (iPS) à partir de cellules épidermiques issues de modèles murins de PE et d’un patient PEC. La correction génique a été obtenue par transfert du gène lentiviral (ferrochélatase ou uroporphyrinogène III synthase (UROS). La pluripotence des cellules iPS a été caractérisée in vitro par la formation de corps embryoïdes et in vivo par la formation de tératomes. In vitro, la correction métabolique a été obtenue après différenciation des cellules iPS humaines en progéniteurs hématopoïétiques. Enfin dans une dernière partie, nous nous sommes intéressés à une approche pharmacologique de la PEC. Nous avons montré que les mutations C73R et P248Q entraînaient une instabilité et une dégradation accélérée de l’UROS par la voie du protéasome. Le traitement de souris UrosP248Q par un inhibiteur du protéasome (Velcade®) a permis la correction de la photosensibilité cutanée. Ces travaux ouvrent de nouvelles perspectives pour le traitement des porphyries érythropoïétiques. / Erythropoietic porphyrias (EP) : Congenital Erythropoietic Porphyria -CEP- and Erythropoietic Protoporphyria -EPP-) are characterized by a deficit of one enzyme implicated in heme biosynthetic pathway. The curative therapy for severe cases of EP is an HLA-compatible Bone Marrow Transplantation (BMT). EPP is sometimes complicated by a major hepatic failure requiring hepatic graft. In a murine model of EPP (Fechm1Pas/Fechm1Pas), we have demonstrated that hepatic lesions progressively appear 2 weeks after birth. Early BMT (in neonates) has made it possible to prevent hepatic lesions and correct skin photosensitivity, demonstrating the efficiency of this therapeutic approach in severe cases of EPP. The gene therapy by graft of corrected autologous hematopoietic stem cells represents an alternative to BMT when HLA-compatible donors are lacking. We have developed induced pluripotent stem cells (iPSC) from epidermic cells of murine models of EP and of one PEC patient. The gene correction was obtained by lentiviral gene transfer (ferrochelatase and uroporphyrinogen III synthase -UROS). The pluripotency of iPSC was characterized in vitro by the formation of embryoid bodies and in vivo by the formation of teratomas. In vitro, the metabolic correction was obtained after differentiation of human IPSC into hematopoietic progenitors. In the last part of this thesis, we have focused on a pharmacological approach of CEP. We have shown that C73R and P248Q mutations lead to instability and accelerated degradation of the UROS protein via the proteasome. Treating UrosP248Q mice with a proteasome inhibitor (Velcade®) has allowed the correction of skin photosensitivity. These works offer new prospects for the treatment of erythropoietic porphyrias.

A síndrome de Prader Willi (PWS) é uma doença de neurodesenvolvimento; a principal hipótese de causa de PWS é a ausência da expressão de SNORD116. O SNORD116 fica na região 15q11-q13 que apresenta vários genes com imprinting genômico e é conhecida por ser controlada pela região de controle de imprinting PWS (PWS-IC) que se localiza sobreposta à região promotora e ao exon 1 do gene SNRPN. Em camundongos, uma proteína zinc finger (Zfp57) foi descrita como importante para o estabelecimento e manutenção do imprinting no Snrpn. Através de análise do ENCODE do Genome Browser, verificamos que outra proteína zinc finger (ZNF274) se liga ao SNORD116. ZNF274 é conhecida por formar um complexo com TRIM28 e SETDB1 que inibe a expressão através da trimetilação da lisina 9 na histona 3 (H3K9me3). No atual estudo mostramos que ZNF274 se liga ao SNORD116 preferencialmente ao alelo materno nas células-tronco pluripotente induzidas (iPSCs). Adicionalmente, as proteínas TRIM28 e SETDB1, que formam um complexo com a ZNF274, estão presentes na região do SNORD116, e a modificação H3K9me3 ocorre preferencialmente no alelo materno nas iPSCs. Na análise funcional, mostramos que o knockdown de SETDB1 isoladamente ou combinado com o knockdown de ZNF274 causa aumento na expressão de SNRPN e SNORD116 nas iPSCs. Além disso, ocorre redução do H3K9me3 e aumento da modificação relacionada à ativação da transcrição, H3K4me2 (dimetilação da lisina 4 na histona 3), na PWS-IC. Os knockdowns também afetam a metilação de DNA, ocasionando o aumento de 5-hidroximetliação de citosinas na PWS-IC. Em outros tipos celulares estudados, neurônios derivados de iPSCs e SHEDs, ZNF274 e a modificação H3K9me3 ocorrem em ambos os alelos dentro do SNORD116. É possível que, nas iPSCs, este complexo proteja a região imprintada da desmetilação do DNA de proteína(s) que atue(m) nessa região somente em células pluripotentes. Nossos achados possibilitam melhor compreensão dos mecanismos envolvidos no imprinting da região 15q11-q13, principalmente do SNORD116, e, consequentemente, disponibiliza novas ferramentas para o desenvolvimento de futuras terapias para PWS. / Prader-Willi syndrome (PWS) is a neurodevelopmental disorder. Loss of paternal copies of the cluster of SNORD116 C/D box snoRNAs and their host transcript, 116HG, on human chromosome 15q11-q13 imprinted region is considered to be the major responsible for PWS. PWS-imprinting center (PWS-IC) regulates 15q11-q13 imprinting. PWS-IC is located upstream and in the exon 1 of SNURF-SNRPN gene. In mice, Zfp57 plays an important role in establishment and maintenance of Snrpn imprinting. In human, ENCODE database indicates that ZNF274 binds to SNORD116. Moreover, ZNF274 are C2H2/KRAB zinc finger proteins as Zfp57. We have investigated the mechanism of repression of the maternal SNORD116. Here, we report that the ZNF274, in association with the histone H3 lysine 9 (H3K9) methyltransferase SETDB1, is part of a complex that binds to the silent maternal but not to the active paternal alleles in induced pluripotent stem cells (iPSCs). Knockdown of SETDB1 in PWS-specific iPSCs causes a decrease in the accumulation of H3K9 trimethylation (H3K9me3) at SNORD116. We also show that upon knockdown of SETDB1 in PWS-specific iPSCs, expression of maternally silenced 116HG RNA is partially restored. SETDB1 knockdown in PWS iPSCs also disrupts DNA methylation at the PWS-IC where a decrease in 5-methylcytosine is observed in association with a concomitant increase in 5-hydroxymethylcytosine. In iPSCs-derived neurons and stem cells from human exfoliated teeth (SHEDs) ZNF274/SETDB1 complex binding and H3K9me3 modification occur in both alleles. These observations suggest that the ZNF274/SETDB1 complex bound to the SNORD116 cluster may protect the PWS-IC from DNA demethylation during early development, as indicated by iPSCs. Our findings reveal novel epigenetic mechanisms that function to repress the maternal 15q11-q13 region. The better understanding of epigenetic mechanisms provides new tools for future therapy research.

Os transtornos do espectro autista (TEA) são um grupo de doenças neuropsiquiátricas caracterizadas por um prejuízo na capacidade de comunicação e de interação social e por padrões comportamentais estereotipados. Os TEA são geneticamente heterogêneos o que dificulta a identificação das alterações genéticas que estão contribuindo para estes transtornos. No presente estudo, selecionamos como uma primeira abordagem o estudo de translocações cromossômicas, buscando encontrar genes candidatos para posteriores estudos funcionais. No primeiro caso, uma translocação de novo balanceada envolvendo os cromossomos 2q11 e Xq24, não identificamos nenhum candidato funcional rompido pelos pontos de quebra. Detectamos ainda a presença de uma isodissomia materna do cromossomo 5 nesta paciente. Este resultado sugere que, possivelmente, tanto a translocação cromossômica quanto a isodissomia devem estar contribuindo para a etiologia do TEA nesta paciente, caracterizando este como um caso de efeito poligênico. Já o estudo da translocação de novo balanceada (3,11)(p21,q22) revelou que o gene TRPC6, um canal de cálcio envolvido no desenvolvimento de dendritos e sinapses excitatórias, encontrava-se rompido no cromossomo 11 deste paciente. As análises dos neurônios e células progenitoras neurais deste paciente obtidas através da técnica de reprogramação celular e o estudo global de expressão gênica sugerem fortemente que o rompimento do gene TRPC6 é o fator etiológico do TEA neste caso. Por fim, nós também realizamos um estudo de expressão gênica global de pacientes autistas idiopáticos e verificamos que os genes diferencialmente expressos nestes pacientes estão principalmente envolvidos na regulação da dinâmica do citoesqueleto, indicando que este pode ser o processo biológico comumente afetado nos pacientes autistas. Nosso trabalho mostra que os estudos citogenéticos são importantes para a identificação de genes candidatos para os TEA e reforça a hipótese de que estes transtornos são causados por diferentes variantes genéticas mas que levam ao comprometimento de um processo biológico comum. Acreditamos que o modelo de reprogramação celular contribuirá para o entendimento da implicação de tais processos na etiologia dos TEA. / Autism spectrum disorders (ASD) are a group of neurodevelopmental diseases characterized by impairments in social and communicative skills and repetitive behaviors. The investigation of ASD causes is hampered by the genetic heterogeneity of these neurodevelopmental diseases. In the present study, we mapped the breakpoints associated to chromosomal translocations found in two autistic patients as a first screening approach, trying to identify single candidate genes that could be further investigated by functional analysis. In the first case, a de novo balanced translocation involving the chromosomes 2q11 and Xq24, we did not find any functionally known relevant gene disrupted by the breakpoints but, surprisingly, SNP-array data showed that the patient also presents a maternally inherited isodisomy on chromosome 5. In this case, is possible that ASD is caused by the combination of the molecular results caused by the translocation and the UPD on chromosome 5, which would characterize this case as an example of polygenic effects on ASD etiology. On the other hand, the study of a second case, a boy with a de novo balanced translocation (3;11)(p21;q22), revealed that TRPC6, a calcium channel involved in dendritic spine and excitatory synapse formation, was disrupted by the translocation on chromosome 11. Making use of cellular reprogramming to generate neurons and neuronal progenitor cells from this patient and expression analysis, we demonstrated that TRPC6 disruption can respond for the phenotype seen in this patient. Finally, we also performed a genome-wide expression analysis to investigate idiopathic autistic patients and we verified that ASD DEGs are mainly implicated in cytoskeleton dynamics, suggesting that the regulation of this cellular structure can be one of the common mechanisms of ASD etiology. Our work shows that cytogenetic studies are important for the identification of ASD candidate genes and reinforces the hypothesis that these disorders are caused by different genetic variants that are implicated in a common biological process. We believe that cellular reprogramming will contribute for the understanding of the implication of such biological processes in the etiology of ASD.

Heart failure is one of the leading causes of death in the United States. Every year in the United States, more than 800,000 people are diagnosed with heart failure and more than 375,000 people die from heart disease. Current therapies such as heart transplants and bioartificial hearts are helpful, but not optimal. Decellularization of porcine whole hearts followed by recellularization with patient-specific human cells may provide the ultimate solution for patients with heart failure. Great progress has been made in the development of efficient processes for decellularization, and the design of automated bioreactors. In this study, the decellularization of porcine hearts was accomplished in 24 h with only 6 h of sodium dodecyl sulfate (SDS) exposure and 98% DNA removal. Automatically controlling the pressure during decellularization reduced the detergent exposure time while still completely removing immunogenic cell debris. Stimulation of macrophages was greatly reduced when comparing native tissue samples to the processed ECM. Complete cell removal was confirmed by analysis of DNA content. General collagen and elastin preservation was demonstrated by SEM and histology. The compression elastic modulus of the ECM after decellularization was lower than native at low strains but there was no significant difference at high strains. Polyurethane casts of the vasculature of native and decellularized hearts demonstrated that the microvasculature network was preserved after decellularization. A static blood thrombosis assay using bovine blood was also developed. A perfusion bioreactor was designed and right ventricle of the decellularized hearts were recellularized with human endothelial cells and cardiac fibroblasts. An effective, reliable, and relatively inexpensive assay based on human blood hemolysis was developed for determining the remaining cytotoxicity of the cECM and the results were consistent with a standard live/dead assay using MS1 endothelial cells incubated with the cECM. Samples from the left ventricle of the hearts were prepared with 300 µm thickness, mounted on 10 mm round glass coverslips. Human induced pluripotent stem cells were differentiated into cardiomyocytes (CMs) and 4 days after differentiation, cardiac progenitors were seeded onto the decellularized cardiac slices. After 10 days, the tissues started to beat spontaneously. Immunofluorescence images showed confluent coverage of CMs on the decellularized slices and the effect of the scaffold was evident in the arrangement of the CMs in the direction of fibers. This study demonstrated the biocompatibility of decellularized porcine hearts with human CMs and the potential of these scaffolds for cardiac tissue engineering. Further studies can be directed toward 3D perfusion recellularization of the hearts and improving repopulation of the scaffolds with various cell types as well as adding mechanical and electrical stimulations to obtain more mature CMs.

Type I diabetes (T1D) is caused by autoimmune destruction of pancreatic β-cells. Immediate consequences of T1D are severe weight loss, ketoacidosis and death unless insulin is administered. The long-term consequences of T1D are dysregulation of metabolism leading to cardiovascular complications, neuropathy and kidney insufficiency. It is estimated that 3 million Americans have T1D, and its prevalence among young individuals is progressively rising. Islet transplantation is the most effective way to treat T1D. Unfortunately, there is a chronic shortage of cadaveric organ donors to treat all of the patients on the waiting list. Thus, an alternative source of insulin producing cells (IPCs) could significantly improve patient treatment. Our lab seeks to establish human induced pluripotent stem (iPS) cells as a novel source of IPCs that are patient tailored. The aim of this thesis was to 1) compare the differentiation of T1D and nondiabetic (ND) patient-derived iPS cells into IPCs, and 2) devise an effective protocol for differentiating skin fibroblast-derived T1D iPS cells into functional, glucose-responsive IPCs. Initially, T1D iPS cells were differentiated into IPCs. However, the yield was very poor. We hypothesized that epigenetic barriers were prevalent in T1D iPS cells, limiting their differentiation into IPCs. To address this problem, we utilized 5-aza-2’-deoxycytidine (5-aza-DC), a potent demethylating agent that inhibits the DNA methyltransferase (Dnmt). We reasoned that the use of a demethylation agent might induce a more labile, permissive state, allowing for greater cell responses to differentiation stimuli. Typically, after the differentiation of T1D iPS cells, several cell cluster types are obtained, namely compact cell clusters and hollow cysts. 5-aza-DC treatment appeared to convert all of the cell clusters into characteristic islet-like compact structures. In contrast, in untreated T1D IPC cultures, we observed the dominant presence of many hollow cysts with only a few tight spheroids. The hollow cysts stained negative for insulin whereas the rare solid spheroids highly expressed insulin. Flow cytometry analysis indicated a much greater percentage of Pdx1+ and insulin+ cells in 5-Aza-DC-treated cultures. These cells express markers typical of pancreatic β-cells, possessed insulin granules in similar quantities as islets, and were glucose-responsive. When transplanted in immunodeficient mice that had developed streptozotozin-induced diabetes, there was a dramatic decrease of hyperglycemia within 28 days. These mice effectively managed glucose challenge by recovering to normoglycemia, whereas nontransplanted mice did not. Altogether, our data for the first time reveal a very high yield of functional IPCs derived from human iPS cells derived from a patient with T1D, which presents a novel alternative source of IPCs that could be used to treat T1D.

The blood system consists of two main lineages: myeloid and lymphoid. The myeloid system consists of cells that are part of the innate immune response while the lymphoid system consist of cells that are part of humoral response. These responses protect our bodies from foreign pathogens. Thus, malignancies in these systems often cause complications and mortality. Scientists world wide have been researching alternatives to treat hematologic disorders and have explored induced pluripotent stem cells (iPSCs) and the conversion of one cell type to another. First, iPS cells were generated by overexpression of four transcription factors: Oct4, Sox2, Klf4 an cMyc. These cells closely resemble embryonic stem cells (ESCs) at the molecular and cellular level. However, the efficiency of cell conversion is less than 0.1%. In addition, many iPS colonies can arise from the same culture, but each has a different molecular signature and potential. Identifying the appropriate iPS cell lines to use for patient specific therapy is crucial. Here we demonstrate that our system is highly efficient in generating iPS cell lines, and cell lines with silent transgenes are most efficient in differentiating to different cell types . Second, we are interested in generating hematopoietic stem cells (HSCs) from fibroblasts directly, without going through the pluripotent state, to increase efficiency and to avoid complications associated with a stem cell intermediate. However, a robust hematopoietic reporter system remains elusive. There are multiple hematopoietic reporter candidates, but we demonstrate that the CD45 gene was the most promising. CD45 is expressed early during hematopoiesis on the surface of HSCs; and as HSCs differentiate CD45 levels increase. Furthermore, the CD45 reporter is only active in hematopoietic cells. We were able to confirm the utility of the CD45 reporter using an in vitro and an in vivo murine model. In conclusion, The goal of this research was to expand the knowledge of stem cell reprogramming, specifically the reprogramming of iPS cells. Furthermore, it is our desire that the CD45 reporter system will undergo further validation and find utility in clinical and cell therapy environments.

Induced pluripotent stem (iPS) cells generated from patients hold great promise for studying diseases that affect the central nervous system, as differentiation into the neuronal lineage creates a limitless supply of affected cells for disease study. Rett syndrome (RTT) is a neurodevelopmental autism spectrum disorder primarily caused by mutations in the methyl-CpG-binding protein 2 (MECP2) gene. Due to the inaccessibility of patient neurons, most of what is known about underlying phenotypes has been described using mouse models. iPS cells provide a potential solution, but reprogramming of patient cells is hampered by low efficiency, and early methods of identifying iPS cells involve transgenic techniques that are not translatable to human patient samples. The first part of this thesis describes the generation and characterization of a pluripotency reporter to address this issue. The EOS lentiviral reporter allows real-time observation of pluripotency changes during reprogramming, and is a useful tool for more efficient isolation of reprogrammed cell lines. Further, the EOS selection system can be used in a disease context to reproducibly mark and maintain disease-specific iPS cell lines for future use in disease modelling. Though iPS cells have been used to study RTT in vitro, extensive assessments of neuron function and electrophysiology have not yet been performed. In the second part of this thesis, iPS cell lines generated from a RTT mouse model were tested for their ability to model disease in vitro. Directed differentiation of multiple Mecp2-deficient and wild-type iPS cell lines to glutamatergic neurons revealed neurons that lack Mecp2 have a smaller soma size, diminished sodium currents, and are less excitable, firing fewer, prolonged action potentials that are smaller in magnitude. This deficiency in intrinsic excitability was accompanied by a dysfunction at excitatory glutamatergic synapses, which together recapitulate changes previously observed in the Mecp2-deficient mouse brain. Having accumulated counts and recordings from hundreds of neurons with consistent responses among lines, the iPS cell system is a representative model of the neuronal and synaptic defects in RTT. These results illustrate the requirement of MeCP2 in normal neuronal function, and suggest altered neuronal homeostasis or aberrant network circuitry may underlie RTT pathogenesis.

The discovery of resetting human somatic cells via introduction of four transcription factors into an embryonic stem cell-like state that enables the generation of any cell type of the human body has revolutionized the field of medical science. The generation of patient-derived iPSCs and the subsequent differentiation into the cells of interest has been, nowadays, widely used as model system for various inherited diseases. The aim of this thesis was to generate iPSCs and to subsequently derive NPCs which can be differentiated into neurons in order to model the two most common forms of the NCLs: LINCL which is caused by mutations within the TPP1 gene, encoding a lysosomal enzyme, and JNCL which is caused by mutations within the CLN3 gene, affecting a lysosomal transmembrane protein. It was shown that patient-derived fibroblasts can be successfully reprogrammed into iPSCs by using retroviral vectors that introduced the four transcription factors POU5F1, SOX2, KLF4 and MYC. The generated iPSCs were subsequently differentiated into expandable NPCs and finally into mature neurons. Phenotype analysis during the different stages, namely pluripotent iPSCs, multipotent NPCs and finally differentiated neurons, revealed a genotype-specific progression of the disease. The earliest events were observed in organelle disruption such as mitochondria, Golgi and ER which preceded the accumulation of subunit c of the mitochondrial ATPase complex that was only apparent in neurons. However, none of these events led to neurodegeneration in vitro. The established disease models recapitulate phenotypes reported in other NCL disease models such as mouse, dog and sheep model systems. More importantly, the hallmark of the NCLs, accumulation of subunit c in neurons, could be reproduced during the course of disease modeling which demonstrates the suitability of the established system. Moreover, the derived expandable NPC populations can be used for further applications in drug screenings. Their robust phenotypes such as low levels of TPP1 activity in LINCL patient-derived NPCs or cytoplasmic vacuoles, containing storage material, observed in CLN3 mutant NPCs, should serve as possible phenotypic read-outs.

No description available.